Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Fluor Selected for Agilent Life Sciences Facility Expansion in Colorado


Fluor Corporation (NYSE: FLR) announced today that its Advanced Technologies & Life Sciences business was selected by Agilent Technologies, Inc., to expand its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado, just north of Denver. Fluor is supporting engineering and procurement as part of the project. The total project value is $725 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230216005795/en/

Fluor Selected for Agilent Life Sciences Facility expansion in Colorado. (Photo: Business Wire)

Fluor Selected for Agilent Life Sciences Facility expansion in Colorado. (Photo: Business Wire)

“Speed to market is essential in the pharmaceutical industry,” said Juan Hernández, president of Fluor’s Advanced Technologies & Life Sciences business. “We will incorporate state-of-the-art engineering enhancements such as advanced automation, water reduction strategies and solvent capturing to optimize cost and construction. This enables us to fast-track the project so that Agilent can meet its global customers’ needs by getting products to market faster.”

Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability. The completed facility will provide for the synthesis, purification and lyophilization of Agilent’s custom nucleic acids therapeutics, also known as oligonucleotides or oligos.

Oligos are short deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) molecules that serve as the active pharmaceutical ingredients for drugs targeting a growing number of diseases, including cancer, cardiovascular disease, and rare and infectious diseases.

Construction is underway with completion expected by 2026.

About Fluor Corporation

Fluor Corporation (NYSE: FLR) is building a better world by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s 41,000 employees provide professional and technical solutions that deliver safe, well-executed, capital-efficient projects to clients around the world. Fluor had revenue of $12.4 billion in 2021 and is ranked 259 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has provided engineering, procurement and construction services for more than 110 years. For more information, please visit www.fluor.com or follow Fluor on Twitter, LinkedIn, Facebook and YouTube.

#atls

View source version on businesswire.com: https://www.businesswire.com/news/home/20230216005795/en/

Fluor Corp. Aktie

45,27 €
0,04 %
Fast unverändert notiert die Fluor Corp. Aktie. Seit gestern hat sich der Kurs um 0,04 % verändert.
Mit 11 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung steht die Community der Fluor Corp. Aktie positiv gegenüber.
Das Kursziel von 47 € für Fluor Corp. weist auf ein leicht positives Potenzial gegenüber dem aktuellen Kurs von 45.27 € hin.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare